#sab-142
Latest news and interesting information about sab-142.
Jefferies Initiates SAB Biotherapeutics with Buy
Jefferies initiates coverage on SAB Biotherapeutics with a Buy rating and $11 target, focusing on SAB-142 diabetes therapy.
...
→
EN ▾
Cause of death of missing architect in Istanbul revealedDiaSorin Sees 2026 Revenue Growth of 5%-6%Maven admits 238,026 new sharesFrench Rep: Sustainability Key to Affordable HousingAuthID Q1 2026 Revenue Jumps 62%Addtech Q4 2025: Robust Growth and ProfitabilityBaku to Clean 3 Lakes: Boyukshor, Zikh, KhojahasanBarclays Options Trades on Nvidia, Halliburton, SnowflakeFull Truck Alliance SWOT analysis: stock faces transformationElia Reaffirms 2026 Guidance, Shares RiseCause of death of missing architect in Istanbul revealedDiaSorin Sees 2026 Revenue Growth of 5%-6%Maven admits 238,026 new sharesFrench Rep: Sustainability Key to Affordable HousingAuthID Q1 2026 Revenue Jumps 62%Addtech Q4 2025: Robust Growth and ProfitabilityBaku to Clean 3 Lakes: Boyukshor, Zikh, KhojahasanBarclays Options Trades on Nvidia, Halliburton, SnowflakeFull Truck Alliance SWOT analysis: stock faces transformationElia Reaffirms 2026 Guidance, Shares Rise